BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 466 filers reported holding BIO-TECHNE CORP in Q1 2021. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $73,173,991 | -16.1% | 1,074,982 | +0.6% | 0.07% | -11.4% |
Q2 2023 | $87,218,524 | +34.3% | 1,068,462 | +22.0% | 0.08% | +27.4% |
Q1 2023 | $64,959,407 | -18.8% | 875,582 | -9.3% | 0.06% | -21.5% |
Q4 2022 | $80,002,738 | +32.1% | 965,284 | +352.5% | 0.08% | +29.5% |
Q3 2022 | $60,579,000 | -17.8% | 213,308 | +0.3% | 0.06% | -11.6% |
Q2 2022 | $73,716,000 | -17.7% | 212,660 | +2.8% | 0.07% | +3.0% |
Q1 2022 | $89,622,000 | -16.7% | 206,959 | -0.5% | 0.07% | -8.2% |
Q4 2021 | $107,631,000 | +6.5% | 208,046 | -0.3% | 0.07% | +1.4% |
Q3 2021 | $101,068,000 | +6.9% | 208,572 | -0.7% | 0.07% | +9.1% |
Q2 2021 | $94,560,000 | +17.4% | 210,013 | -0.4% | 0.07% | +10.0% |
Q1 2021 | $80,520,000 | +20.5% | 210,824 | +0.2% | 0.06% | +15.4% |
Q4 2020 | $66,832,000 | +25.7% | 210,462 | -2.0% | 0.05% | +13.0% |
Q3 2020 | $53,178,000 | -5.7% | 214,662 | +0.5% | 0.05% | -9.8% |
Q2 2020 | $56,394,000 | +142.3% | 213,558 | +74.0% | 0.05% | +104.0% |
Q1 2020 | $23,279,000 | – | 122,768 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |